发布于: Android转发:0回复:0喜欢:0

大跌。

$Apellis制药(APLS)$ 补体

APLS Q2 total U.S. net product revenues of $89.6M - including $67.3M for SYFOVRE and $22.3M for EMPAVELI.

Cash and cash equivalents of $616.3M; expected cash runway into Q1'25